Literature DB >> 29275464

The Role of Tumor Microenvironment in Cancer Immunotherapy.

Timothy Frankel1,2, Mirna Perusina Lanfranca1,2, Weiping Zou3,4,5.   

Abstract

The field of tumor immunology and immunotherapy has undergone a renaissance in the past decade do in large part to a better understanding of the tumor immune microenvironment. After suffering countless successes and setbacks in the twentieth century, immunotherapy has now come to the forefront of cancer research and is recognized as an important tool in the anti-tumor armamentarium. The goal of therapy is to aid the immune system in recognition and destruction of tumor cells by enhancing its ability to react to tumor antigens. This traditionally has been accomplished by induction of adaptive immunity through vaccination or through passive delivery of immunologic effectors as in the case of adoptive cell transfer. The recent discovery of immune "checkpoints" whose purpose is to suppress immune activity and prevent auto-immunity has created a new angle by which reactivity to tumors can be enhanced. Blockers of these checkpoints have yielded impressive clinical results and have recently been approved for use in a wide variety of malignancies. With data showing increasing rates of not only treatment response, but complete remissions, immunotherapy is poised to become an increasingly utilized therapy in the treatment of cancer.

Entities:  

Keywords:  B7-H1; CAR T cell; CTLA4; Cytokine; Dendritic cell; IL-2; PD-1; T cell; Tumor

Mesh:

Year:  2017        PMID: 29275464     DOI: 10.1007/978-3-319-67577-0_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  48 in total

1.  RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunity.

Authors:  Zhuo Zhang; Lin Luo; Chuan Xing; Yu Chen; Peng Xu; Mao Li; Ling Zeng; Chao Li; Sadashib Ghosh; Deborah Della Manna; Tim Townes; William J Britt; Narendra Wajapeyee; Barry P Sleckman; Zechen Chong; Jianmei Wu Leavenworth; Eddy S Yang
Journal:  Nat Cancer       Date:  2021-10-22

Review 2.  Kinetics of Nanomedicine in Tumor Spheroid as an In Vitro Model System for Efficient Tumor-Targeted Drug Delivery With Insights From Mathematical Models.

Authors:  Sayoni Maitra Roy; Vrinda Garg; Sourav Barman; Chitrita Ghosh; Amit Ranjan Maity; Surya K Ghosh
Journal:  Front Bioeng Biotechnol       Date:  2021-12-01

3.  A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.

Authors:  Xuewen Wang; Chengfei Zhao; Dandan Huang; Zhoujie Liu; Mengmeng Liu; Fei Lin; Yingyu Lu; Jing Jia; Liqing Lin; Xinhua Lin; Huangyuan Li; Zhiwei Chen
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

4.  Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.

Authors:  Xi Chen; Yixiao Yuan; Wenjun Ren; Fan Zhou; Xiaobin Huang; Jun Pu; Xiaoqun Niu; Xiulin Jiang
Journal:  Front Oncol       Date:  2022-06-03       Impact factor: 5.738

5.  Targeting breast cancer with a combination of DNT and LAG3 checkpoint blockage and its mechanism.

Authors:  Miao Wang; Yuhan Wei; Yingrui Li; Hongzhong Li; Jiangtao Jin; Yuting Lu; Qin Li
Journal:  Immun Inflamm Dis       Date:  2022-08

Review 6.  Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives.

Authors:  Evangelos Koustas; Eleni-Myrto Trifylli; Panagiotis Sarantis; Nikolaos Papadopoulos; Eleni Karapedi; Georgios Aloizos; Christos Damaskos; Nikolaos Garmpis; Anna Garmpi; Kostas A Papavassiliou; Michalis V Karamouzis; Athanasios G Papavassiliou
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

Review 7.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

8.  Antitumor effects of targeted killing of tumor-associated macrophages under photothermal conditions.

Authors:  Bo Wang; Ying Huang
Journal:  Lasers Med Sci       Date:  2021-01-13       Impact factor: 3.161

9.  A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.

Authors:  Jie Wu; Lan Li; Huibo Zhang; Yaqi Zhao; Haohan Zhang; Siyi Wu; Bin Xu
Journal:  Oncogene       Date:  2021-06-09       Impact factor: 9.867

10.  A comprehensive analysis of tumor microenvironment-related genes in colon cancer.

Authors:  R Luo; W Guo; H Wang
Journal:  Clin Transl Oncol       Date:  2021-03-10       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.